Ronald B Goldberg1, Vera A Bittner2, Richard L Dunbar3, Jerome L Fleg4, George Grunberger5, John R Guyton6, Lawrence A Leiter7, Ruth McBride8, Jennifer G Robinson9, Debra L Simmons10, Carol Wysham11, Ping Xu12, William E Boden13. 1. Division of Endocrinology, Metabolism and Diabetes, University of Miami Miller School of Medicine, Fla. 2. Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham School of Medicine. 3. Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 4. Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, Md. 5. Grunberger Diabetes Institute, Bloomfield Hills, Mich. 6. Duke University Medical Center, Durham, NC. 7. Division of Endocrinology and Metabolism, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michaels Hospital, Toronto, Ont, Canada. 8. Axio Research, LLC, Seattle, Wash. Electronic address: ruthm@axioresearch.com. 9. College of Public Health & Carver College of Medicine, University of Iowa, Iowa City. 10. Division of Endocrinology, Department of Internal Medicine, University of Utah, Salt Lake City. 11. Rockwood Diabetes and Endocrinology, Spokane, Wash. 12. PPD, Wilmington, NC. 13. Department of Medicine, Albany VA Medical Center, NY.
Abstract
BACKGROUND:Niacin is an antidyslipidemic agent that may cause blood sugar elevation in patients with diabetes, but its effects on glucose and insulin values in nondiabetic statin-treated subjects with cardiovascular disease and at high risk for diabetes are less well known. METHODS: This was a prespecified, intent-to-treat analysis of the Atherothrombosis Intervention in Metabolic syndrome with low high-density lipoprotein/high triglycerides: Impact on Global Health outcomes trial which randomized 3,414 participants at 92 centers in the US and Canada to extended-releaseniacin (ERN) plus simvastatin/ezetimibe (ERN) or simvastatin/ezetimibe plus placebo (Placebo). Baseline and annual fasting glucose and insulin values were measured. Those experiencing an adverse event indicative of diabetes or starting medications for diabetes were considered to have confirmed diabetes. In addition, nondiabetic subjects with 2 annual follow-up glucose measurements were categorized into normal, impaired fasting glucose or newly diagnosed diabetes (presumed or confirmed) states. RESULTS: Compared with placebo, ERN increased annual fasting glucose from baseline to 1 year in both those with normal (7.9 ± 15.8 vs 4.3 ± 10.3 mg/dL; P < .001) and impaired fasting glucose (4.1 ± 18.7 vs 1.4 ± 14.9; P < .02) and increased insulin levels. Both effects waned over the next 2 years. There were less consistent effects in those with baseline diabetes. There was an increased risk of progressing from normal to presumed or confirmed impaired fasting glucose (ERN 197/336) cases (58.6%) vs placebo 135/325 cases (41.5%; P < .001) over time, but no difference in diabetes development in the 2 treatment groups except in those with normal fasting glucose at baseline. CONCLUSIONS: The addition of ERN to simvastatin/ezetimibe had marginal effects on glycemia in those with diabetes at baseline, and there was a trend toward increased development of new-onset diabetes. In addition, ERN increased the risk of developing impaired fasting glucose, which may have deleterious consequences over time and warrants further study.
RCT Entities:
BACKGROUND:Niacin is an antidyslipidemic agent that may cause blood sugar elevation in patients with diabetes, but its effects on glucose and insulin values in nondiabetic statin-treated subjects with cardiovascular disease and at high risk for diabetes are less well known. METHODS: This was a prespecified, intent-to-treat analysis of the Atherothrombosis Intervention in Metabolic syndrome with low high-density lipoprotein/high triglycerides: Impact on Global Health outcomes trial which randomized 3,414 participants at 92 centers in the US and Canada to extended-release niacin (ERN) plus simvastatin/ezetimibe (ERN) or simvastatin/ezetimibe plus placebo (Placebo). Baseline and annual fasting glucose and insulin values were measured. Those experiencing an adverse event indicative of diabetes or starting medications for diabetes were considered to have confirmed diabetes. In addition, nondiabetic subjects with 2 annual follow-up glucose measurements were categorized into normal, impaired fasting glucose or newly diagnosed diabetes (presumed or confirmed) states. RESULTS: Compared with placebo, ERN increased annual fasting glucose from baseline to 1 year in both those with normal (7.9 ± 15.8 vs 4.3 ± 10.3 mg/dL; P < .001) and impaired fasting glucose (4.1 ± 18.7 vs 1.4 ± 14.9; P < .02) and increased insulin levels. Both effects waned over the next 2 years. There were less consistent effects in those with baseline diabetes. There was an increased risk of progressing from normal to presumed or confirmed impaired fasting glucose (ERN 197/336) cases (58.6%) vs placebo 135/325 cases (41.5%; P < .001) over time, but no difference in diabetes development in the 2 treatment groups except in those with normal fasting glucose at baseline. CONCLUSIONS: The addition of ERN to simvastatin/ezetimibe had marginal effects on glycemia in those with diabetes at baseline, and there was a trend toward increased development of new-onset diabetes. In addition, ERN increased the risk of developing impaired fasting glucose, which may have deleterious consequences over time and warrants further study.
Authors: Veena Rajanna; Kristen B Campbell; Jeffrey Leimberger; Bibhu D Mohanty; John R Guyton Journal: J Clin Lipidol Date: 2011-12-23 Impact factor: 4.766
Authors: M B Elam; D B Hunninghake; K B Davis; R Garg; C Johnson; D Egan; J B Kostis; D S Sheps; E A Brinton Journal: JAMA Date: 2000-09-13 Impact factor: 56.272
Authors: William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245
Authors: S L Edelstein; W C Knowler; R P Bain; R Andres; E L Barrett-Connor; G K Dowse; S M Haffner; D J Pettitt; J D Sorkin; D C Muller; V R Collins; R F Hamman Journal: Diabetes Date: 1997-04 Impact factor: 9.461
Authors: Naveed Sattar; David Preiss; Heather M Murray; Paul Welsh; Brendan M Buckley; Anton J M de Craen; Sreenivasa Rao Kondapally Seshasai; John J McMurray; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G Westendorp; James Shepherd; Barry R Davis; Sara L Pressel; Roberto Marchioli; Rosa Maria Marfisi; Aldo P Maggioni; Luigi Tavazzi; Gianni Tognoni; John Kjekshus; Terje R Pedersen; Thomas J Cook; Antonio M Gotto; Michael B Clearfield; John R Downs; Haruo Nakamura; Yasuo Ohashi; Kyoichi Mizuno; Kausik K Ray; Ian Ford Journal: Lancet Date: 2010-02-16 Impact factor: 79.321
Authors: John R Guyton; Sergio Fazio; Adeniyi J Adewale; Erin Jensen; Joanne E Tomassini; Arvind Shah; Andrew M Tershakovec Journal: Diabetes Care Date: 2012-02-14 Impact factor: 19.112
Authors: Stefan Schandelmaier; Matthias Briel; Ramon Saccilotto; Kelechi K Olu; Armon Arpagaus; Lars G Hemkens; Alain J Nordmann Journal: Cochrane Database Syst Rev Date: 2017-06-14
Authors: Radmila Lyubarova; Jennifer G Robinson; Michael Miller; Debra L Simmons; Ping Xu; Beth L Abramson; Marshall B Elam; Todd M Brown; Ruth McBride; Jerome L Fleg; Patrice Desvigne-Nickens; Woubeshet Ayenew; William E Boden Journal: J Clin Lipidol Date: 2017-07-05 Impact factor: 4.766
Authors: Zahid Ahmad; Poulabi Banerjee; Sara Hamon; Kuo-Chen Chan; Aurelie Bouzelmat; William J Sasiela; Robert Pordy; Scott Mellis; Hayes Dansky; Daniel A Gipe; Richard L Dunbar Journal: Circulation Date: 2019-06-27 Impact factor: 29.690
Authors: Artem V Artiukhov; Aneta Grabarska; Ewelina Gumbarewicz; Vasily A Aleshin; Thilo Kähne; Toshihiro Obata; Alexey V Kazantsev; Nikolay V Lukashev; Andrzej Stepulak; Alisdair R Fernie; Victoria I Bunik Journal: Sci Rep Date: 2020-02-05 Impact factor: 4.379